DMARDs对类风湿关节炎患者瓜氨酸化肽自身抗体水平的影响:一项纵向分析
这项纵向观察研究纳入100例接受稳定DMARD治疗的RA患者,每6个月检测抗CCP2 IgG和总IgG水平,持续2.5年。结果显示,RTX和ABA显著降低抗CCP2抗体水平,而MTX、TNFi和TCZ无显著影响;仅RTX同时显著降低总IgG水平。
要点
- RTX和ABA显著降低RA患者抗CCP2 IgG水平,MTX、TNFi和TCZ无显著影响。
- 仅RTX在2.5年治疗期间同时显著降低总IgG水平。
- 靶向适应性免疫的DMARDs对瓜氨酸化肽自身抗体水平有显著降低作用。
核心结论
- 靶向适应性免疫的DMARDs如ABA和RTX显著降低抗CCP2 IgG水平,而细胞因子抑制剂和甲氨蝶呤无显著影响。
- RTX是唯一同时降低总IgG水平的DMARD。
研究设计与样本
- 纵向观察性研究,纳入100例RA患者,每6个月检测抗CCP2 IgG抗体(U/L)和总IgG水平(mg/dL),总观察期2.5年。
- 所有患者在此期间接受稳定DMARD治疗,分为5组各20例:MTX单药、TNFi、TCZ、RTX和ABA。
主要发现
- MTX组抗CCP2抗体水平变化为-24.1 ± 8.1%,TNFi组为-14.0 ± 11.1%,TCZ组为-24.3 ± 11.3%,均无显著变化。
- RTX组抗CCP2抗体水平显著下降-75.6 ± 4.4%,ABA组显著下降-82.5 ± 3.7%。
- 总IgG水平在MTX组(-1.6 ± 3.5%)、TNFi组(2.5 ± 3.4%)、TCZ组(-4.4 ± 3.1%)和ABA组(-2.4 ± 3.8%)均无显著变化。
- RTX组总IgG水平显著下降-22.0 ± 3.7%。
- 5组基线人口学和疾病特异性特征具有可比性。
临床怎么用
- 对于接受RTX或ABA治疗的RA患者,抗CCP2抗体水平可能显著下降,可考虑监测其变化。
- 接受RTX治疗的患者需关注总IgG水平下降,警惕免疫球蛋白降低相关风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether stable treatment with DMARDs affects anti-CCP2 antibody levels in patients with rheumatoid arthritis. METHODS: In this longitudinal observational study 100 RA patients were followed for anti-CCP2 IgG antibody (U/L) and total IgG level (mg/dL) every 6 months for a total period of 2.5 years. All patients received stable DMARD treatment during this period. Five groups comprising each 20 patients were analyzed as follows: (1) methotrexate (MTX) alone, (2) tumor necrosis factor inhibitors (TNFi), (3) tocilizumab (TCZ), (4) rituximab (RTX), and (5) abatacept (ABA). RESULTS: Baseline demographic and disease-specific characteristics were comparable between the 5 groups. Anti-CCP2 antibody levels did not show significant changes in patients treated with MTX (mean ± SEM: -24.1 ± 8.1%), TNFi (-14.0 ± 11.1%) or TCZ (-24.3 ± 11.3%) between baseline and the 2.5 years follow-up. In contrast, anti-CCP2 antibody levels significantly decreased during treatment with RTX (-75.6 ± 4.4%) and ABA (-82.5 ± 3.7%). With respect to total IgG levels, no significant changes were observed with MTX (-1.6 ± 3.5%), TNFi (2.5 ± 3.4%), TCZ (-4.4 ± 3.1%), or ABA (-2.4 ± 3.8%) over 2.5 years. In contrast, total IgG levels significantly decreased during treatment with RTX (-22.0 ± 3.7%). CONCLUSIONS: DMARDs targeting the adaptive immune response such as ABA and RTX significantly lowered anti-CCP2 IgG levels, while cytokine inhibitors and methotrexate had no significant effects on anti-CCP2 IgG levels. RTX is the only DMARD, which also lowers total IgG level.
引用
- Wunderlich C, Oliviera I, Figueiredo CP, et al. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis. Semin Arthritis Rheum. 2016. PMID: 28109618. doi:10.1016/j.semarthrit.2016.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。